Bull
$4.12
Scenario price
$1.880
+0.030 (+1.62%)At close
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
PetMed Express Inc is currently trading at $1.88, which is significantly below the proposed acquisition price of $3.00 per share by SilverCape Investments. However, the company has reported a negative net income of -$6,145,000 for the last quarter, indicating ongoing financial struggles. The RSI is at 65.325, suggesting the stock is nearing overbought territory, while insiders have increased their buying activity by 174.01%, which could signal confidence in the company's future. Given these mixed signals, it may be prudent to hold rather than buy at this time.
Morgan Stanley
$3.2
2025-04-17
Morgan Stanley
2025-04-17
Price Target
$3.2
Lake Street
$3.5
2024-08-07
Lake Street
2024-08-07
Price Target
$3.5
Morgan Stanley
$3.5
2024-06-12
Morgan Stanley
2024-06-12
Price Target
$3.5
Lake Street
$7
2024-06-12
Lake Street
2024-06-12
Price Target
$7
Lake Street
$9
2024-02-09
Lake Street
2024-02-09
Price Target
$9
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

PetMed Express Enters $37M Sale-Leaseback Agreement for Headquarters

PetMed Express Receives Acquisition Proposal from SilverCape

SilverCape Revises Acquisition Proposal for PetMed Express

NASDAQ 100 Pre-Market Indicator Rises Significantly

SilverCape Revises Acquisition Proposal for PetMed Express
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).
PetMed Express Inc is currently trading at $1.88, which is significantly below the proposed acquisition price of $3.00 per share by SilverCape Investments. However, the company has reported a negative net income of -$6,145,000 for the last quarter, indicating ongoing financial struggles. The RSI is at 65.325, suggesting the stock is nearing overbought territory, while insiders have increased their buying activity by 174.01%, which could signal confidence in the company's future. Given these mixed signals, it may be prudent to hold rather than buy at this time.
5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.